Fiera Capital Corp Buys 48,317 Shares of argenex SE $ARGX

Fiera Capital Corp lifted its stake in argenex SE (NASDAQ:ARGX) by 27.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 225,971 shares of the company’s stock after acquiring an additional 48,317 shares during the period. Fiera Capital Corp’s holdings in argenex were worth $190,030,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Abound Wealth Management grew its holdings in argenex by 3,200.0% in the 4th quarter. Abound Wealth Management now owns 33 shares of the company’s stock valued at $28,000 after buying an additional 32 shares during the last quarter. Sound Income Strategies LLC acquired a new stake in argenex in the 4th quarter valued at approximately $28,000. Ameriflex Group Inc. acquired a new stake in argenex in the 3rd quarter valued at approximately $32,000. Sunbelt Securities Inc. acquired a new stake in argenex in the 3rd quarter valued at approximately $36,000. Finally, Aventura Private Wealth LLC acquired a new stake in argenex in the 4th quarter valued at approximately $38,000. Institutional investors and hedge funds own 60.32% of the company’s stock.

Wall Street Analysts Forecast Growth

ARGX has been the topic of a number of research analyst reports. Deutsche Bank Aktiengesellschaft raised argenex from a “hold” rating to a “buy” rating in a report on Tuesday, March 10th. Wells Fargo & Company raised their target price on argenex from $1,260.00 to $1,291.00 and gave the company an “overweight” rating in a report on Monday, June 1st. Wall Street Zen lowered argenex from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Oppenheimer lowered their target price on argenex from $1,060.00 to $1,014.00 and set an “outperform” rating on the stock in a report on Thursday, April 2nd. Finally, Robert W. Baird raised their target price on argenex from $858.00 to $867.00 and gave the company a “neutral” rating in a report on Friday, February 27th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $1,019.50.

argenex Stock Performance

Shares of NASDAQ:ARGX opened at $891.32 on Monday. argenex SE has a 1-year low of $510.05 and a 1-year high of $934.62. The firm has a market capitalization of $55.43 billion, a PE ratio of 39.68, a PEG ratio of 1.36 and a beta of 0.47. The business’s 50 day moving average is $794.90 and its 200-day moving average is $812.60.

argenex (NASDAQ:ARGX) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $5.52 earnings per share for the quarter. argenex had a return on equity of 44.37% and a net margin of 31.31%.The company had revenue of $1.31 billion for the quarter. On average, sell-side analysts predict that argenex SE will post 26.25 EPS for the current year.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.